Based on these findings, Intellia chose the 50 mg dose for their Phase 3 research, HAELO, which is now under enrollment ...

Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary ...

For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...

Inc. took a nosedive today, dropping around 20% after the company announced results from the Phase 2 study of its investigational gene-editing therapy, NTLA-2002, for hereditary angioedema (HAE).

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

A single dose of the CRISPR-based gene-editing therapy NTLA-2002 reduced angioedema attacks and led to sustained reduction in ...

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...

NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE) NTLA-2002 is Intellia’s second in vivo candidate ...